Orexo AB (publ) (STO:ORX)
20.30
-0.05 (-0.25%)
Apr 14, 2026, 5:29 PM CET
Orexo AB Revenue
In the year 2025, Orexo AB had annual revenue of 26.00M SEK, down -12.46%. Orexo AB had revenue of 3.30M in the quarter ending December 31, 2025.
Revenue
26.00M
Revenue Growth
-12.46%
P/S Ratio
27.27
Revenue / Employee
351.35K
Employees
74
Market Cap
708.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.00M | -3.70M | -12.46% |
| Dec 31, 2024 | 29.70M | -609.10M | -95.35% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.54B |
| EQL Pharma AB | 425.75M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 55.94M |
| Enzymatica AB | 53.90M |
| Cereno Scientific AB | 44.27M |
| Newbury Pharmaceuticals AB | 36.76M |
| Moberg Pharma AB | 13.54M |
Orexo AB News
- 5 weeks ago - Invitation & Agenda: Orexo R&D Day on March 24 - PRNewsWire
- 5 weeks ago - Orexo changes the organizational structure and management team to increase focus on development of new products - PRNewsWire
- 7 months ago - Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - PRNewsWire
- 11 months ago - Orexo to present clinical data for OX640 at the EAACI Congress - PRNewsWire
- 1 year ago - Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology - PRNewsWire
- 1 year ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire
- 1 year ago - Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology - PRNewsWire
- 1 year ago - Orexo initiates new study of OX640 in participants with allergic rhinitis - PRNewsWire